Aimto evaluate potential therapeutic effects of Atorvastatin on experimental heart failure in rats induced by doxorubicin (Dox), and clinically on patients with chronic heart failure. Rats received treatment (for 6 weeks) divided into (n=10 each group); control saline treated rats (1ml, IP), Dox-treated rats (2.5mg/kg, IP) as heart failure group, Atorvastatin-Dox treated rats (10mg/Kg orally), and digoxin-Dox treated rats (0.02mg/kg orally). Clinically, 40 patients with heart failure of EF% <45, divided into 20 control cases, received standard anti-failure treatment only and 20 tested group patients received standard anti-failure treatment plus Atorvastatin (40 mg/day) for 6 weeks. Sera of rats and patients taken for evaluating lipid profiles, high sensitive C-reactive protein (hs-CRP), cardiac troponin-T (cTn-T) and malondialdehyde (MDA). Heart tissues of rats were histologically evaluated. Echocardiographic examination done for both patient groups. Atorvastatin treated rat group showed a significant improvement in signs of heart failure, an increase of systolic blood pressure and body weight, reduced the mortality rate and also, their lipid profiles, cTn-T, hs-CRP, and cardiac MDA levels were significantly reduced in comparison to other groups. Histo logically, less cardiac necrosis and fibrosis with enhancement of neo-vascularisation in cardiac tissues in atorvastatin treated rats. Clinically, patients taken Atorvastatin, had a significant reduction in lipid profiles, cTn-T, hs-CRP, MDA and improvement of heart function parameters (increased of LV-EF and FS%; decreased EDD and ESD) versus controls. Atorvastatin could be a beneficial addition to traditionally anti-heart failure therapy; due to its potential pleiotropic properties independent of their cholesterol-lowering